glp-1 agonist and dpp-4 inhibitor Glucagon-like peptide-1 Comparison of GLP-1 receptor agonists

Additionally, a large-scale observational study involving over 40,000 Chinese OA patients with comorbid T2DM reported that GLP-1RA therapies offered disease-modifying benefits [49]

GLP-1based therapies share several common adverse effects and carry some rare but important risks

According to the CDC, as of 2021, 38.1 million adults (14.7%) in the United States had diabetes, with the incidence increasing with age

Cureus 15, e38630

Endothelial GLP-1 (Glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension

Animal studies, particularly in rodents, have shown that high-dose GLP-1 exposure can lead to pancreatic ductal proliferation and, in some cases, inflammatory changes